Chemistry for peptide and protein PEGylation

被引:1280
作者
Roberts, MJ [1 ]
Bentley, MD [1 ]
Harris, JM [1 ]
机构
[1] Shearwater Corp, Huntsville, AL 35806 USA
关键词
PEGylation; PEG-protein; PEG conjugation; PEG chemistry;
D O I
10.1016/S0169-409X(02)00022-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Poly(ethylene glycol) (PEG) is a highly investigated polymer for the covalent modification of biological macromolecules and surfaces for many pharmaceutical and biotechnical applications. In the modification of biological macromolecules, peptides and proteins are of extreme importance, Reasons for PEGylation (i.e. the covalent attachment of PEG) of peptides and proteins are numerous and include shielding of antigenic and immunogenic epitopes, shielding receptor-mediated uptake by the reticuloendothelial system (RES), and preventing recognition and degradation by proteolytic enzymes. PEG conjugation also increases the apparent size of the polypeptide, thus reducing the renal filtration and altering biodistribution. An important aspect of PEGylation is the incorporation of various PEG functional groups that are used to attach the PEG to the peptide or protein. In this paper, we review PEG chemistry and methods of preparation with a particular focus on new (second-generation) PEG derivatives, reversible conjugation and PEG structures. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:459 / 476
页数:18
相关论文
共 68 条
  • [31] Harris JM, 1999, Patent No. [WO 99/45964, 9945964]
  • [32] Poly(ethylene glycol)s with reactive endgroups .2. Practical consideration for the preparation of protein-PEG conjugates
    Hooftman, G
    Herman, S
    Schacht, E
    [J]. JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, 1996, 11 (02) : 135 - 159
  • [33] The crystal structure of human interferon beta at 2.2-angstrom resolution
    Karpusas, M
    Nolte, M
    Benton, CB
    Meier, W
    Lipscomb, WN
    Goelz, S
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (22) : 11813 - 11818
  • [34] Characterization and stability of N-terminally PEGylated rhG-CSF
    Kinstler, OB
    Brems, DN
    Lauren, SL
    Paige, AG
    Hamburger, JB
    Treuheit, MJ
    [J]. PHARMACEUTICAL RESEARCH, 1996, 13 (07) : 996 - 1002
  • [35] Kinstler OB, 1999, US Patent, Patent No. [5: 985: 265, 5985265]
  • [36] THE SYNTHESIS OF SUBSTITUTED METHOXY-POLY(ETHYLENEGLYCOL) DERIVATIVES SUITABLE FOR SELECTIVE PROTEIN MODIFICATION
    KOGAN, TP
    [J]. SYNTHETIC COMMUNICATIONS, 1992, 22 (16) : 2417 - 2424
  • [37] Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C
    Kozlowski, A
    Harris, JM
    [J]. JOURNAL OF CONTROLLED RELEASE, 2001, 72 (1-3) : 217 - 224
  • [38] Drug delivery systems employing 1,6-elimination: Releasable poly(ethylene glycol) conjugates of proteins
    Lee, S
    Greenwald, RB
    McGuire, J
    Yang, K
    Shi, C
    [J]. BIOCONJUGATE CHEMISTRY, 2001, 12 (02) : 163 - 169
  • [39] Lee S., 1999, US Patent, Patent No. [5,985263, 5985263]
  • [40] BIOLOGICAL AND PHARMACOKINETIC PROPERTIES OF A NOVEL IMMUNOGLOBULIN-CD4 FUSION PROTEIN
    LYCZAK, JB
    MORRISON, SL
    [J]. ARCHIVES OF VIROLOGY, 1994, 139 (1-2) : 189 - 196